Baker McKenzie Advises McKesson on its USD 2.25 Billion Acquisition of Precision Medicine Group

Baker McKenzie is acting as international counsel to McKesson Corporation (NYSE: MCK) on its acquisition of Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services for approximately USD 2.25 billion.

Led by M&A Partner Darcy Down, the core team included:

Corporate / M&A:      Collin Stich, Angus Duncan
IP / Data:                  Adam Aft, Keo McKenzie, Robby Turner
Regulatory:               Lois Sheng Liu, Jing Xu
Employment:            Kimberly Franko, Benjamin Durst
Compensation:         M'Alyssa Mecenas, Sesen Hailemichael, Jill Sparkman
Real Estate:              Sarah Swain

Lawyers from around the Firm formed part of Baker McKenzie’s wider transactional team.

Learn more about the transaction: McKesson Signs Agreement to Acquire Precision Medicine Group, LLC

Baker McKenzie is a global transactional leader, with more than 2,500 deal practitioners across 40+ countries advising on complex and cross‑border transactions. With one of the largest Healthcare & Life Sciences teams of any international law firm, the Firm combines deep sector knowledge and a global platform to execute high‑stakes matters at the intersection of innovation, regulation and M&A.